Pivotal role of xanthine oxidase in the initiation of tubulointerstitial renal injury in rats with hyperlipidemia

Kidney International

Volumn 69, Issue 3, 2006, Pages 481-487

  Gwinner, W ^a   Scheuer, H ^a   Haller, H ^a   Brandes, R P ^b   Groene, H J ^c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Antioxidant enzymes; Macrophage; MCP 1; Reactive oxygen species; VCAM 1

Indexed keywords

ANTIOXIDANT; CELL ADHESION MOLECULE; GLUTATHIONE PEROXIDASE; MONOCYTE CHEMOTACTIC PROTEIN 1; REACTIVE OXYGEN METABOLITE; VASCULAR CELL ADHESION MOLECULE 1; XANTHINE OXIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; COMPARATIVE STUDY; CONTROLLED STUDY; DIET; ENZYME ACTIVITY; ENZYME INHIBITION; HISTOLOGY; HYPERLIPIDEMIA; KIDNEY INJURY; KIDNEY PROXIMAL TUBULE; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; UPREGULATION;

ANIMALS; ANTIOXIDANTS; CELL ADHESION MOLECULES; CHEMOKINE CCL2; ECTODYSPLASINS; GLOMERULONEPHRITIS; HYPERLIPIDEMIAS; IMMUNOHISTOCHEMISTRY; KIDNEY TUBULES; MACROPHAGES; MALE; MEMBRANE PROTEINS; NEPHRITIS, INTERSTITIAL; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; TUMOR NECROSIS FACTORS; UP-REGULATION; VASCULAR CELL ADHESION MOLECULE-1; XANTHINE OXIDASE;

EID: 31544478848     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000121     Document Type: Article

References (44)

1. Attman PO, Alaupovic P, Samuelsson O. Lipoprotein abnormalities as a risk factor for progressive nondiabetic renal disease. Kidney Int 1999; 56(Suppl 71): S14-S17.
2. Syrjanen J, Mustonen J, Pasternack A. Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant 2000; 15: 34-42.
3. Massy ZA, Khoa TN, Lacour B et al. Dyslipidaemia and the progression of renal disease in chronic renal failure patients. Nephrol Dial Transplant 1999; 14: 2392-2397.
4. Samuelsson O, Mulec H, Knight-Gibson C et al. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant 1997; 12: 1908-1915.
5. Eddy AA. Interstitial inflammation and fibrosis in rats with diet-induced hypercholesterolemia. Kidney Int 1996; 50: 1139-1149.
6. Grone HJ, Walli A, Grone E et al. Induction of glomerulosclerosis by dietary lipids. A functional and morphologic study in the rat. Lab Invest 1989; 60: 433-446.
7. Kasiske BL, O'Donnell MP, Cleary MP, Keane WF. Effects of reduced renal mass on tissue lipids and renal injury in hyperlipidemic rats. Kidney Int 1989; 35: 40-47.
8. Lee HS, Jeong JY, Kim BC et al. Dietary antioxidant inhibits lipoprotein oxidation and renal injury in experimental focal segmental glomerulosclerosis. Kidney Int 1997; 51: 1151-1159.
9. Scheuer H, Gwinner W, Hohbach J et al. Oxidant stress in hyperlipidemia-induced renal damage. Am J Physiol 2000; 278: F63-F74.
10. Sarnesto A, Linder N, Raivio KO. Organ distribution and molecular forms of human xanthine dehydrogenase/xanthine oxidase protein. Lab Invest 1996; 74: 48-56.
11. Hattori M, Nikolic-Paterson DJ, Miyazaki K et al. Mechanisms of glomerular macrophage infiltration in lipid-induced renal injury. Kidney Int 1999; 56(Suppl 71): S47-S50.
12. Kodama N, Otani H, Yamada Y et al. Involvement of MCP-1 and M-CSF in glomerular foam cell formation in ExHC rats. Kidney Int 1999; 56(Suppl 71): S174-S177.
13. Marui N, Offermann MK, Swerlick R et al. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest 1993; 92: 1866-1874.
14. 2 and tumor necrosis factor-alpha in endothelial and epithelial cells. J Biol Chem 1997; 272: 32910-32918.
15. Satriano JA, Shuldiner M, Hora K et al. Oxygen radicals as second messengers for expression of the monocyte chemoattractant protein JE/MCP-1, and the monocyte colony-stimulating factor, CSF-1, in response to tumor necrosis factor-alpha and immunoglobulin G. Evidence for involvement of reduced nicotinamide adenine dinucleotide phosphate (NADPH)-dependent oxidase. J Clin Invest 1993; 92: 1564-1571.
16. Joles JA, Kunter U, Janssen U et al. Early mechanisms of renal injury in hypercholesterolemic or hypertriglyceridemic rats. J Am Soc Nephrol 2000; 11: 669-683.
17. Ong AC, Moorhead JF. Tubular lipidosis: epiphenomenon or pathogenetic lesion in human renal disease? Kidney Int 1994; 45: 753-762.
18. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993; 91: 2546-2551.
19. Mugge A, Brandes RP, Boger RH et al. Vascular release of superoxide radicals is enhanced in hypercholesterolemic rabbits. J Cardiovasc Pharmacol 1994; 24: 994-998.
20. Thomas ME, Schreiner GF. Contribution of proteinuria to progressive renal injury: consequences of tubular uptake of fatty acid bearing albumin. Am J Nephrol 1993; 13: 385-398.
21. Thomas JP, Geiger PG, Girotti AW. Lethal damage to endothelial cells by oxidized low density lipoprotein: role of selenoperoxidases in cytoprotection against lipid hydroperoxide- and iron-mediated reactions. J Lipid Res 1993; 34: 479-490.
22. Gwinner W, Grone HJ. Role of reactive oxygen species in glomerulonephritis. Nephrol Dial Transplant 2000; 15: 1127-1132.
23. Johnson JL, Waud WR, Cohen HJ, Rajagopalan KV. Molecular basis of the biological function of molybdenum. Molybdenum-free xanthine oxidase from livers of tungsten-treated rats. J Biol Chem 1974; 249: 5056-5061.
24. Gosling J, Slaymaker S, Gu L et al. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 1999; 103: 773-778.
25. Attman PO, Samuelsson O, Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis 1993; 21: 573-592.
26. Vogel RA, Corretti MC, Gellman J. Cholesterol, cholesterol lowering, and endothelial function. Prog Cardiovasc Dis 1998; 41: 117-136.
27. Kojda G, Harrison D. Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res 1999; 43: 562-571.
28. Cardillo C, Kilcoyne CM, Cannon RO et al. Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension 1997; 30: 57-63.
29. Spiekermann S, Landmesser U, Dikalov S et al. Electron spin resonance characterization of vascular xanthine and NAD(P)H oxidase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation 2003; 107: 1383-1389.
30. Bosmans JL, Holvoet P, Dauwe SE et al. Oxidative modification of low-density lipoproteins and the outcome of renal allografts at 1 1/2 years. Kidney Int 2001; 59: 2346-2356.
31. Dimeny E, Tufveson G, Lithell H et al. The influence of pretransplant lipoprotein abnormalities on the early results of renal transplantation. Eur J Clin Invest 1993; 23: 572-579.
32. Dimeny E, Wahlberg J, Lithell H, Fellstrom B. Hyperlipidaemia in renal transplantation - risk factor for long-term graft outcome. Eur J Clin Invest 1995; 25: 574-583.
33. Guijarro C, Massy ZA, Kasiske BL. Clinical correlation between renal allograft failure and hyperlipidemia. Kidney Int 1995; 48(Suppl 52): S56-S59.
34. Salahudeen A, Wang C, McDaniel O et al. Antioxidant lazaroid U-74006F improves renal function and reduces the expression of cytokines, inducible nitric oxide synthase, and MHC antigens in a syngeneic renal transplant model. Partial support for the response-to-injury hypothesis. Transplantation 1996; 62: 1628-1633.
35. Grimm M, Spiecker M, De Caterina R et al. Inhibition of major histocompatibility complex class II gene transcription by nitric oxide and antioxidants. J Biol Chem 2002; 277: 26460-26467.
36. Olbricht CJ, Wanner C, Thiery J, Basten A. Simvastatin in nephrotic syndrome. Simvastatin in Nephrotic Syndrome Study Group. Kidney Int 1999; 56(Suppl 71): S113-S116.
37. Yukawa S, Mune M, Yamada Y et al. Ongoing clinical trials of lipid reduction therapy in patients with renal disease. Kidney Int 1999; 56(Suppl 71): S141-S143.
38. Gwinner W, Plasger J, Brandes RP et al. Role of xanthine oxidase in passive Heymann nephritis in rats. J Am Soc Nephrol 1999; 10: 538-544.
39. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
40. Gwinner W, Deters-Evers U, Brandes RP et al. Antioxidant-oxidant balance in the glomerulus and proximal tubule of the rat kidney. J Physiol (London) 1998; 509: 599-606.
41. Gwinner W, Landmesser U, Brandes RP et al. Reactive oxygen species and antioxidant defense in puromycin aminonucleoside glomerulopathy. J Am Soc Nephrol 1997; 8: 1722-1731.
42. Kahl R, Weimann A, Weinke S, Hildebrandt AG. Detection of oxygen activation and determination of the activity of antioxidants towards reactive oxygen species by use of the chemiluminigenic probes luminol and lucigenin. Arch Toxicol 1987; 60: 158-162.
43. Wang CS, Smith RL. Lowry determination of protein in the presence of Triton X-100. Anal Biochem 1975; 63: 414-417.
44. Saksela M, Raivio KO. Cloning and expression in vitro of human xanthine dehydrogenase/oxidase. Biochem J 1996; 315: 235-239.